Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 37,670

Document Document Title
WO/2019/040104A3
The present disclosure relates to compounds according to Formulae (I), (II) and (VIII), useful for treating diseases.  
WO/2019/075136A1
The present disclosure provides compounds and methods of use thereof for treating inflammatory diseases or disorders.  
WO/2019/074995A1
The present disclosure concerns a method for preparing florasulam which involves treating a solution of 2,6-difluoroaniline in 1,2-propylene glycol with: a) sulfonyl chloride III and then b) a base to provide, after workup and isolation,...  
WO/2019/074962A1
Described herein are compounds, methods of making such compounds, pharmaceutical compositions, and medicaments comprising such compounds, and methods of using such compounds to treat cancer. (II), or a pharmaceutically acceptable salt th...  
WO/2019/040106A3
The present disclosure relates to compounds according to Formulae disclosed herein, useful for treating diseases.  
WO/2019/074810A1
The present invention is directed to substituted certain reversed indazole compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1A, R1B, X, Y, RZ and R2 are as defined herein, which are potent inhibitors of L...  
WO/2019/072942A1
The invention provides novel compounds having the general formula (I) or pharmaceutically acceptable salts thereof, wherein RA, RB1, RB2, the A ring and the B ring are as described herein, pharmaceutical compositions including the compou...  
WO/2019/074824A1
The present invention provides compounds of formula (I): wherein all of the variables are as defined herein. These compounds are inhibitors of indoleamine 2,3-dioxygenase (IDO), which may be used as medicaments for the treatment of proli...  
WO/2019/040105A3
The present disclosure relates to compounds according to Formula (I), treating diseases.  
WO/2019/075291A1
The invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof as described herin. The invention also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compoun...  
WO/2019/074081A1
[Problem] Provided are: a salt of (4-fluorophenyl)[(8R)-8-methyl-3-(3-methyl-1,2,4-thiadiazol- 5-yl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]meth anone; and a crystal of the salt. [Solution] Studies have been made on salts of (...  
WO/2019/072906A1
The invention relates to compounds of formula (I): wherein the variables are defined in the specification. The invention also relates to a pesticidal mixture comprising a compound of formula (I), and another agrochemically active ingredi...  
WO/2019/038428A3
The invention relates to a method for measuring and representing the temperature in three dimensions, in particular in living tissue by using nuclear magnetic resonance (NMR), and to the use of novel metal organic complexes as contrast m...  
WO/2019/074979A1
Heterocyclic compounds as Weel inhibitors are provided. The compounds may find therapeutic agents for the treatment of diseases and may find particular use in oncology.  
WO/2019/072944A1
The present invention relates to a method for preparing 3- [ ( 4S ) -8-bromo-l-methyl-6- (pyridin-2-yl ) -4H-imidazo [1,2- a] [ 1, 4 ] benzodiazepin-4-yl ] -propionic acid methyl ester starting from 3- [ (3S) -7-bromo-2-oxo-5- (pyridin-2...  
WO/2019/074809A1
The present invention is directed to substituted certain reversed indazolyl-spiro[2.2]pentane-carbonitrile derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, X, Y, and Z are as defined herein, ...  
WO/2019/073253A1
This invention relates to pyrrolopyrimidine comprising compounds that may be useful as inhibitors of Mitogen-activated Protein Kinase Kinase Kinase Kinase-4 (MAP4K4). The invention also relates to the use of these pyrrolopyrimidine compr...  
WO/2019/075358A1
Described herein are compounds of the formulae (I)-(III) as well as pharmaceutical compositions comprising such compounds and methods for using such compounds/pharmaceutical compositions for treating Alzheimer's disease.  
WO/2019/070083A1
Provided are: a novel compound which can be used to produce an organic electroluminescent (EL) element exhibiting outstanding performance; an organic EL element containing said compound; and an electronic device equipped with said organi...  
WO/2019/031618A8
The present invention provides a compound represented by formula [I], the compound exhibiting the effect of inhibiting an enzyme that produces 20-HETE, or a pharmaceutically acceptable salt thereof. (In formula [I], the structure represe...  
WO/2019/069275A1
The present invention relates to methods of treating disease states, including cancer, in a human comprising systemically administering a STING agonist, or a pharmaceutically acceptable salt thereof, to said human.  
WO/2019/068679A1
The present invention relates to compounds of the formula (1 ) which are suitable for use in electronic devices, in particular organic electroluminescent devices, and to electronic devices which comprise these compounds.  
WO/2019/070709A1
The present invention provides compounds, compositions and methods for treating and/or preventing a flavivirus infection by administering such compounds and compositions.  
WO/2019/070082A1
A compound represented by formula (1) is used. (In formula (1), in a pair selected from R4 and R5, R5 and R6, and R6 and R7, one represents a single bond which bonds with *a and the other represents a single bond which bonds with *b of a...  
WO/2019/070698A1
The present disclosure is related to forms of ibrutinib, i.e., crystalline Form H pyridine solvate of ibrutinib Form H, crystalline Form I pyridine solvate of ibrutinib and an amorphous form of ibrutinib. The present disclosure also rela...  
WO/2019/065283A1
Provided are a novel pyridazinone compound or a salt thereof useful as an active ingredient of an herbicide and an herbicide and control method using the same. A pyridazinone compound represented by general formula (I) or a salt thereof....  
WO/2019/067523A1
Provided herein are fluoro-substituted porphyrin compounds, such as those having a structure represented by Formula (I), wherein R1 is a C1-C8 alkyl that is substituted with at least 1 fluorine (e.g., a C1-C8 alkyl substituted with 1-17 ...  
WO/2019/062876A1
Provided are a fluorescent probe, a preparation method therefor and a use thereof. The fluorescent probe responds to viscosity sensitively and specifically, can be used for the specific fluorescence label of proteins, and can also be use...  
WO/2019/062435A1
Provided in the present invention are a compound represented by general formula I, a pharmaceutically acceptable salt, enantiomer, diastereoisomer or racemate thereof, a preparation method therefor, a pharmaceutical composition containin...  
WO/2019/067843A1
Disclosed herein are novel compounds of formula (I) and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure furthe...  
WO/2019/062854A1
The present invention relates to co-crystals of ribociclib and co-crystals of ribociclib mono-succinate, comprising co-crystals between ribociclib and saccharin, co-crystals between ribociclib and cholic acid, co-crystals between ribocic...  
WO/2019/067396A1
Disclosed are compounds of formulas (I) and (V) and compositions thereof useful as inhibitors of ZAP-70 kinase. Also provided are methods of synthesis and methods of use of ZAP-70 inhibitors in treating individuals suffering from organ t...  
WO/2019/067594A1
The present application provides salt forms of N-(4-(4-Amino-7-(1- isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)p henyl)-1- isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrim idine-5- carboxamide (I) and N-(4-(4-A...  
WO/2019/063696A1
The invention relates to primary para-phenylenediamine compounds substituted with an aliphatic chain comprising a cationic heterocyclic group according to formula (I), as well as the organic or mineral acid or base addition salts thereof...  
WO/2019/062733A1
The present invention falls within the technical field of medicine, and in particular relates to PDE9 inhibitor compounds as shown in formula (I) or pharmaceutically acceptable salts or stereoisomers thereof, and also relates to pharmace...  
WO/2019/065516A1
A compound represented by formula (II), an N-oxide compound or a salt thereof. [Chemical formula 1] In formula (II), R1 represents a hydrogen atom, a substituted or unsubstituted C1-6 alkyl group or a halogeno group; R2 represents a subs...  
WO/2019/062686A1
Disclosed in the present invention are a compound with cyanobenzene as the core, and an application of the compound in OLED devices. The compound has cyanobenzene as the core and a carbazole cyclic group as a branched chain. The compound...  
WO/2019/065043A1
Provided are a compound production method capable of producing a benzothiol compound having little coloration, a composition, and a curable composition. The method is for producing a compound represented by formula (1) and comprises reac...  
WO/2019/063708A1
The present invention covers substituted 3-Phenylquinazolin-4(3H)-one compounds of general formula (I) as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, phar...  
WO/2019/065964A1
Provided are: a novel antibody-pyrrolodiazepine derivative; a novel antibody-pyrrolodiazepine derivative conjugate using the same; and novel CLDN6 antibody and/or CLDN9 antibody.  
WO/2019/065791A1
Provided is a compound which has an MAGL inhibitory effect and is expected to be useful as a prophylactic or therapeutic agent for neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, Hutchinson's disease, amyotrop...  
WO/2019/062329A1
Provided are a 4,6,7-trisubstituted 1,2-dihydropyrrol[3,4-c]pyridin/pyrimidin-3-one derivative and a preparation method and pharmaceutical use thereof. In particular, the present invention relates to a compound of formula (I) or a pharma...  
WO/2019/063288A1
The invention relates to an organic compound, in particular for the use in optoelectronic devices. According to the invention, the organic compound has - a first chemical moiety with a structure of formula (I), and - two second chemical ...  
WO/2019/062328A1
The present invention relates to a 1,2-dihydropyrrol[3,4-c]pyridin/pyrimidin-3-one derivative substituted by N-(3-aminophenyl)acrylamide and a preparation method and pharmaceutical use thereof. In particular, the present invention relate...  
WO/2019/067961A1
The invention relates to novel salts of 7-methyl-2-[4-methyl-6-[4-(trifluoromethyl)- phenyl]pyrimidin-2-yl]-1,7-diazaspiro[4.4]nonan-6-one, to compositions containing said salts and to the use of said salts in treating diseases and condi...  
WO/2019/057121A1
Disclosed in the present invention are a salt form, crystal form of an Rho protein kinase inhibitor, preparation method therefor and medical use thereof.  
WO/2019/057660A1
The present invention relates to heteroaryl compounds of formula (Ia) or a compound in the form of a stereoisomer, an agriculturally acceptable salt, a tautomer,an isotopic form, a N-oxide or a S-oxide thereof. The present invention furt...  
WO/2019/056466A1
The present invention relates to a compound having the structure of formula I or a pharmaceutically acceptable salt, solvate, active metabolite, polymorph, ester, optical isomer or prodrug thereof, a pharmaceutical composition comprising...  
WO/2019/056375A1
The present invention relates to a slightly acidic environment-sensitive and ketal-linked gefitinib axially substituted silicon phthalocyanine complex and a preparation method therefor and a medical use thereof. In particular, the presen...  
WO/2019/057757A1
The specification generally relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, where R1-R4, A and X have the meanings defined herein. The specification also relates to the use of compounds of Formula (I) a...  

Matches 1 - 50 out of 37,670